• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

贝伐单抗治疗期间出现的瘤样脱髓鞘病变。

Tumefactive demyelination presenting during bevacizumab treatment.

作者信息

Rice Claire M, Rossiter David, Fehmi Janev, Stevens James C, Renowden Shelley A, Cohen Nicki, Bailey Clare, Scolding Neil J

机构信息

Department of Neurology, North Bristol, NHS Trust Bristol, UK School of Clinical Sciences, University of Bristol, Bristol, UK.

Department of Neurology, North Bristol, NHS Trust Bristol, UK.

出版信息

BMJ Case Rep. 2015 Dec 16;2015:bcr2015212173. doi: 10.1136/bcr-2015-212173.

DOI:10.1136/bcr-2015-212173
PMID:26677151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4691864/
Abstract

We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.

摘要

我们报告了玻璃体内注射贝伐单抗（阿瓦斯汀）治疗期间出现的肿胀性脱髓鞘病变。鉴于贝伐单抗目前正被评估为视神经脊髓炎（另一种脱髓鞘疾病）的潜在治疗选择，这一发现具有特别重要的意义。

相似文献

1
Tumefactive demyelination presenting during bevacizumab treatment.贝伐单抗治疗期间出现的瘤样脱髓鞘病变。
BMJ Case Rep. 2015 Dec 16;2015:bcr2015212173. doi: 10.1136/bcr-2015-212173.
2
Safety and complications of intravitreal injections performed in an Asian population in Singapore.新加坡亚洲人群玻璃体内注射的安全性与并发症
Int Ophthalmol. 2017 Apr;37(2):325-332. doi: 10.1007/s10792-016-0241-4. Epub 2016 May 28.
3
Using intravitreal bevacizumab (Avastin) - Indian Scenario.使用玻璃体内注射贝伐单抗（阿瓦斯汀）——印度的情况。
Indian J Ophthalmol. 2017 Jul;65(7):545-548. doi: 10.4103/ijo.IJO_431_17.
4
[Intravitreal bevacizumab for choroidal neovascularization associated with Best's disease].玻璃体内注射贝伐单抗治疗与Best病相关的脉络膜新生血管
Arch Soc Esp Oftalmol. 2014 Oct;89(10):405-7. doi: 10.1016/j.oftal.2013.07.002. Epub 2014 Feb 5.
5
Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study.玻璃体腔注射贝伐单抗联合维替泊芬光动力疗法与单纯玻璃体腔注射贝伐单抗治疗年龄相关性黄斑变性所致脉络膜新生血管的1年随访研究
Digit J Ophthalmol. 2016 Jun 30;22(2):46-53. doi: 10.5693/djo.01.2014.01.004. eCollection 2016.
6
FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.影响玻璃体腔内注射贝伐单抗治疗近视性脉络膜新生血管后再次治疗需求及长期视力预后的因素
Retina. 2015 Dec;35(12):2457-68. doi: 10.1097/IAE.0000000000000610.
7
Intravitreal bevacizumab for idiopathic choroidal neovascularization.玻璃体内注射贝伐单抗治疗特发性脉络膜新生血管化。
J AAPOS. 2009 Jun;13(3):296-8. doi: 10.1016/j.jaapos.2008.12.003. Epub 2009 Mar 14.
8
Rescue therapy with intravitreal aflibercept for choroidal neovascularization secondary to choroidal osteoma non-responder to intravitreal bevacizumab and ranibizumab.玻璃体内注射阿柏西普对脉络膜骨瘤继发脉络膜新生血管进行挽救治疗，此类患者对玻璃体内注射贝伐单抗和雷珠单抗无反应。
Int Ophthalmol. 2015 Jun;35(3):441-4. doi: 10.1007/s10792-015-0059-5. Epub 2015 Mar 12.
9
Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.玻璃体内注射贝伐单抗治疗年龄相关性黄斑变性中心凹下脉络膜新生血管：泛美视网膜协作研究组12个月随访结果
Retina. 2008 Nov-Dec;28(10):1387-94. doi: 10.1097/IAE.0b013e3181884ff4.
10
The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.国际玻璃体腔内注射贝伐单抗安全性调查：利用互联网评估全球药物安全性。
Br J Ophthalmol. 2006 Nov;90(11):1344-9. doi: 10.1136/bjo.2006.099598. Epub 2006 Jul 19.

引用本文的文献

1
B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders.作为视神经脊髓炎谱系障碍治疗干预靶点的B细胞和抗体
Pharmaceuticals (Basel). 2021 Jan 6;14(1):37. doi: 10.3390/ph14010037.
2
Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.抗 PD-1 抗体纳武利尤单抗治疗后发生的视神经脊髓炎谱系疾病：首例报告。
BMC Cancer. 2018 Jan 24;18(1):95. doi: 10.1186/s12885-018-3997-2.

本文引用的文献

1
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.一名多发性硬化症患者在服用芬戈莫德治疗期间及之后出现肿胀性脱髓鞘病变及恶性病程。
J Neurol Sci. 2014 Sep 15;344(1-2):193-7. doi: 10.1016/j.jns.2014.06.013. Epub 2014 Jun 17.
2
Tumefactive multiple sclerosis and fingolimod.
J Neurol Sci. 2014 Sep 15;344(1-2):1-2. doi: 10.1016/j.jns.2014.06.022. Epub 2014 Jun 24.
3
Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T-cell responses.贝伐单抗通过抑制脊髓血管生成和减少外周 T 细胞反应来减轻实验性自身免疫性脑脊髓炎。
J Neuropathol Exp Neurol. 2012 Nov;71(11):983-99. doi: 10.1097/NEN.0b013e3182724831.
4
Retrobulbar optic neuritis in a bevacizumab-treated patient with metastatic breast cancer.一名接受贝伐单抗治疗的转移性乳腺癌患者发生球后视神经炎。
Breast J. 2012 Sep;18(5):502-3. doi: 10.1111/j.1524-4741.2012.01293.x. Epub 2012 Aug 15.
5
Sera from neuromyelitis optica patients disrupt the blood-brain barrier.视神经脊髓炎患者的血清会破坏血脑屏障。
J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):288-97. doi: 10.1136/jnnp-2011-300434. Epub 2011 Nov 19.
6
The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis.血管内皮生长因子 A 的表达在复发性进展型多发性硬化症患者的外周血单个核细胞中被下调。
PLoS One. 2011 May 6;6(5):e19138. doi: 10.1371/journal.pone.0019138.
7
An unusual optic disc neovascularization in a case of intermediate uveitis associated with multiple sclerosis.一例与多发性硬化相关的中间葡萄膜炎患者出现的罕见视盘新生血管形成。
Eur J Ophthalmol. 2008 Nov-Dec;18(6):1020-2. doi: 10.1177/112067210801800629.